XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.21.4

DEBT (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2021
DEBT |
Schedule of term loans | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Principal Amount |  | ​ |  | ​ |  | ​ |  | ​
​ | ​ | as of date of Credit | ​ | ​ | ​ | Monthly | ​ | ​ | ​ | ​
​ | ​ | Agreement | ​ | Annual | ​ | Payment | ​ | ​ | ​ | ​
​ | ​ | April 30, 2021 | ​ | Interest | ​ | Amount | ​ | ​ | ​ | ​
Loan Name | ​ | (000) | ​ | Rate | ​ | (000) | ​ | Maturity Date | ​ | Use of Proceeds
Term Loan 1 | ​ | $ | 3,980 |  | 5.20 | % | $ | 36 | ​ | March 28, 2025 |  | Funded expansion of building on real property in Mount Vernon, IN
Term Loan 2 | ​ | $ | 3,571 |  | 5.06 | % | $ | 78 | ​ | July 2, 2023 |  | Funded a portion of the cash consideration for the Seventh Wave Laboratories acquisition
Term Loan 3 | ​ | $ | 1,076 |  | 5.20 | % | $ | 32 | ​ | March 28, 2025 |  | Funded equipment needs associated with expansion of real property in Mount Vernon, IN
Term Loan 4 | ​ | $ | 1,001 |  | 4.63 | % | $ | 20 | ​ | November 1, 2025 |  | Funded the cash consideration for the Smithers Avanza acquisition
Term Loan 5 | ​ | $ | 810 |  | 4.00 | % | $ | 17 | ​ | June 30, 2025 |  | Funded certain capital expenditures
Term Loan 6 | ​ | $ | 2,865 |  | 4.25 | % | $ | 56 | ​ | December 31, 2025 |  | Funded certain capital expenditures
Term Loan 7 | ​ | $ | 1,263 |  | 4.00 | % | $ | 28 | ​ | June 1, 2025 |  | Financed aspects of the Pre-Clinical Research Services and related real property acquisitions
Term Loan 8 | ​ | $ | 1,853 |  | 4.00 | % | $ | 12 | ​ | December 1, 2024 |  | Financed aspects of the Pre-Clinical Research Services and related real property acquisitions
Term Loan 9 | ​ | $ | 10,000 |  | 3.85 | % | $ | 184 (a) | ​ | April 30, 2026 |  | Funded a portion of the cash consideration of the Bolder BioPATH merger
Term Loan 10 | ​ | $ | 5,000 |  | 3.85 | % | $ | 92 (a) | ​ | April 30, 2026 |  | Funded a portion of the cash consideration of the HistoTox Labs acquisition
Term Loan 11 | ​ | $ | 3,622 |  | 3.99 | % | $ | 33 | ​ | June 23, 2022 |  | Refinanced debt with The Huntington Bank for general business purposes
Term Loan 12 | ​ | $ | 4,832 (b) |  | 3.85 | % | $ | 10 (c) | ​ | December 26, 2026 |  | Financed the acquisition of the St. Louis facility and associated expansion
(a) | See Mandatory Prepayments information below
(b) | Principal amount as of May 26, 2021
(c) | The Monthly payment amount increases to $29 on January 1, 2022
Schedule of weighted-average assumptions used to compute the fair-value | ​
​ | ​ | ​ | ​
​ | ​ | 2021 | ​
Risk-free interest rate |  | 1.20 | %
Dividend yield |  | — | %
Volatility of the expected market price of the Company’s common shares |  | 81.10 | %
Maturity period (years) |  | 6.04 | ​
Schedule of long-term debt | Long-term debt is detailed in the table below. ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of September 30:
​ |  | 2021 |  | 2020
Term Loan #1 | ​ | $ | 3,888 | ​ | $ | 4,230
Term Loan #2 | ​ |  | 3,255 | ​ |  | 4,004
Term Loan #3 | ​ | ​ | 963 | ​ | ​ | 1,266
Term Loan #4 | ​ | ​ | 920 | ​ | ​ | 1,115
Term Loan #5 | ​ | ​ | 737 | ​ | ​ | 920
Term Loan #6 | ​ | ​ | 2,590 | ​ | ​ | —
Term Loan #7 | ​ |  | 1,145 | ​ |  | 1,425
Term Loan #8 | ​ | ​ | 1,825 | ​ | ​ | 1,891
Term Loan #9 | ​ | ​ | 9,395 | ​ | ​ | —
Term Loan #10 | ​ | ​ | 4,697 | ​ | ​ | —
Term Loan #11 | ​ | ​ | 3,495 | ​ | ​ | 3,748
Term Loan #12 | ​ | ​ | 3,275 | ​ | ​ | —
Subtotal Term Loans | ​ | ​ | 36,185 | ​ | ​ | 18,599
Seller Note – Bolder BioPATH | ​ |  | 1,500 | ​ |  | —
Seller Note – Smithers Avanza | ​ |  | 280 | ​ |  | 650
Seller Note – Preclinical Research Services | ​ | ​ | 685 | ​ | ​ | 752
Paycheck protection program loan | ​ | ​ | — | ​ | ​ | 5,051
Convertible Senior Notes | ​ | ​ | 131,673 | ​ | ​ | —
​ | ​ |  | 170,323 | ​ |  | 25,052
Less: Current portion | ​ |  | (9,656) | ​ |  | (5,991)
Less: Debt issue costs not amortized | ​ |  | (6,458) | ​ |  | (235)
Total Long-term debt | ​ | $ | 154,209 | ​ | $ | 18,826
Schedule of maturities of long-term debt | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026 |  | Thereafter |  | Total
Long-term debt(a) |  | $ | 550 |  | $ | 363 |  | $ | 412 |  | $ | 869 |  | $ | 270 |  | $ | 131,673 | ​ | $ | 134,137
(a) excludes indebtedness to FIB repaid in November 2021. Refer to Note 16

X
- Definition Tabular disclosure of term loans. + References No definition available. + Details
Name: | notv_ScheduleOfTermLoanTableTextBlock
Namespace Prefix: | notv_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(e),(f)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of maturity and sinking fund requirement for long-term debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601 + Details
Name: | us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration